Zeniquin: Product Information (Page 3 of 3)
Cats
Marbofloxacin was administered for 42 consecutive days to 24 cats approximately 8 months old (8 cats per treatment group) at the dosages of 2.5, 7.5 and 12.5 mg/lb/day (5.5, 16.5 and 27.5 mg/kg/day). Treatment with marbofloxacin did not produce adverse effects on body weights, food consumption, serum chemistry, urinalysis or organ weight parameters. Decreased segmented neutrophil counts were observed in some cats in all treatment groups, including the placebo group, but mean counts were significantly lower in the marbofloxacin-treated groups. In some cats, absolute neutrophil counts were below normal reference values (as low as 615 neutrophils/μL in a marbofloxacin-treated cat and as low as 882 neutrophils/μL in a placebo-treated cat). Other hematological observations were not adversely affected. Clinical signs were occasionally noted in cats in the highest dosage group: excessive salivation in 4/8 cats and redness of ear pinnae in 2/8 cats. Macroscopic changes in the articular cartilage of femurs were seen in one cat receiving 7.5 mg/lb and in 3 cats receiving 12.5 mg/lb. Microscopically, these gross lesions were related to a focal or multifocal chondropathy. Microscopic chondropathy not associated with macroscopic observations was also present in one cat treated with 2.5 mg/lb daily (1X the upper end of the dose range) and one additional cat treated with 7.5 mg/lb daily. There was no evidence of lameness during the course of the study. A perivascular to diffuse dermatitis was seen microscopically in one mid-dose cat and 4 high-dose cats. Funduscopic exam by a board-certified ophthalmologist and histologic examination of retina and optic nerve by ocular pathologists revealed no lesions in any of the treatment groups.
Marbofloxacin was also administered orally to 6 cats approximately 8 months of age for 14 consecutive days at a dosage of 25 mg/lb/day (55 mg/kg/day). Clinical signs associated with drug intolerance were excessive salivation in 5/6 cats and redness of ear pinnae in all cats after 8 days of treatment. Emesis was noted occasionally in several cats and diminished activity was noted in one cat. Decreased food intake was noted in some animals, primarily males, when compared to controls. Perivascular to diffuse dermatitis was seen microscopically in the pinnae of all treated animals and in the standard skin samples of several animals. There was focal or multifocal articular chondropathy in 2/6 treated animals. One treated cat had a duodenal mucosal erosion and one treated cat had a pyloric ulcer. There were no observations of lameness and no adverse effects on hematology, clinical chemistry, urinalysis, or organ weight parameters. Funduscopic examination by a board-certified ophthalmologist and histologic examination of retina and optic nerve by ocular pathologists revealed no lesions.
A study was conducted to investigate the effect of marbofloxacin on articular cartilage of skeletally mature cats 12–14 months of age. Forty cats were randomly assigned to 4 groups of 10 cats each. Groups received placebo or marbofloxacin at dosages of 1.25, 3.75 or 7.5 mg/lb/day (2.75, 8.25 or 16.5 mg/kg/day) for 42 consecutive days. There were no treatment-related pathological changes in the joints or other tissues. Emesis and soft stools was noted in all treatment groups, including placebo, and increased in frequency with increasing dose and duration of treatment. Emesis was more apparent in the high-dose males.
STORAGE CONDITIONS
Store below 30°C (86°F).
HOW SUPPLIED
Zeniquin tablets are available in the following strengths of marbofloxacin and bottle sizes:
25 mg scored tablets supplied in bottles that contain 100 or 250 tablets
50 mg scored tablets supplied in bottles that contain 100 or 250 tablets
100 mg scored tablets supplied in a 50 tablet bottle
200 mg scored tablets supplied in a 50 tablet bottle
REFERENCES
1. Schneider M, et al: Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Therap 19:56–61, 1996.
To report suspected adverse effects, and/or obtain a copy of the MSDS, call 1-888-963-8471.
Approved by FDA under NADA # 141-151
zoetis
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
40027358
Revised: May 2019
PRINCIPAL DISPLAY PANEL — 25 mg Bottle Label
Zeniquin®
(marbofloxacin)
Tablets
For oral use in dogs and cats only
Antibacterial
Caution: Federal law restricts
this drug to use by or on the
order of a licensed veterinarian.
Federal law prohibits the
extralabel use of this drugin food-producing animals.
25 mg
100 Tablets
Approved by FDA under NADA # 141-151
zoetis
PRINCIPAL DISPLAY PANEL — 50 mg Bottle Label
PRINCIPAL DISPLAY PANEL — 100 mg Bottle Label
PRINCIPAL DISPLAY PANEL — 200 mg Bottle Label
| ZENIQUIN marbofloxacin tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ZENIQUIN marbofloxacin tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ZENIQUIN marbofloxacin tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ZENIQUIN marbofloxacin tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| Labeler — Zoetis Inc. (828851555) |
Revised: 10/2019 Zoetis Inc.
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.